AN
The startup develops a selective ALDH2 inhibitor that regulates dopamine levels to mitigate cravings associated with substance use disorders. This technology enables patients to overcome addiction to drugs, alcohol, and smoking without altering their baseline dopamine levels.
Updated 3 months ago
Funding
$10.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops a selective ALDH2 inhibitor that regulates dopamine levels to mitigate cravings associated with substance use disorders. This technology enables patients to overcome addiction to drugs, alcohol, and smoking without altering their baseline dopamine levels.